Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 4.4% – Time to Sell?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) fell 4.4% during mid-day trading on Monday . The company traded as low as $32.50 and last traded at $32.3350. 5,424 shares were traded during trading, a decline of 97% from the average session volume of 211,740 shares. The stock had previously closed at $33.84.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 price objective on the stock. Citigroup began coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $55.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Needham & Company LLC started coverage on shares of Sensei Biotherapeutics in a research report on Friday, August 21st. They issued a “buy” rating and a $56.00 price target on the stock. Finally, Loop Capital set a $50.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sensei Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Sensei Biotherapeutics Stock Performance

The firm has a market cap of $891.74 million, a PE ratio of -0.24 and a beta of -0.28. The business has a 50-day moving average of $28.93.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.04) by $2.20. Sell-side analysts forecast that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brian C. Stephenson acquired 5,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were purchased at an average price of $23.50 per share, for a total transaction of $117,500.00. Following the acquisition, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. This represents a 11.99% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were bought at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 49,494 shares of company stock worth $1,188,822 over the last ninety days. 7.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. purchased a new position in shares of Sensei Biotherapeutics in the second quarter worth approximately $3,610,000. Vivo Capital LLC purchased a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at approximately $22,758,000. Bank of America Corp DE grew its position in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics during the 1st quarter worth approximately $4,188,000. Finally, Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the period. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.